United Kingdom-based ViiV Healthcare has revealed positive results for its phase three BRIGHTE study of investigational Fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV-1 infection, it was reported yesterday.
The product, in combination with optimised background treatment, maintained virologic suppression from Week 24 to Week 48 in this difficult-to-treat population. Results indicated 54% of patients in the randomised cohort (n = 146/272) achieved virologic suppression (
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results